Affiliations
AffiliationsItem in Clipboard
Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American SeniorsDebra Patt et al. JCO Clin Cancer Inform. 2020 Nov.
doi: 10.1200/CCI.20.00134. AffiliationsItem in Clipboard
AbstractPurpose: While the immediate care and access disruptions associated with the COVID-19 pandemic have received growing attention in certain areas, the full range of gaps in cancer screenings and treatment is not yet well understood or well documented throughout the country comprehensively.
Methods: This study used a large medical claims clearinghouse database representing 5%-7% of the Medicare fee-for-service population to characterize changes in the utilization of cancer care services and gain insight into the impact of COVID-19 on the US cancer population, including identification of new patients, gaps in access to care, and disruption of treatment journeys.
Results: In March-July 2020, in comparison with the baseline period of March-July 2019, there is a substantial decrease in cancer screenings, visits, therapy, and surgeries, with variation by cancer type and site of service. At the peak of the pandemic in April, screenings for breast, colon, prostate, and lung cancers were lower by 85%, 75%, 74%, and 56%, respectively. Significant utilization reductions were observed in April for hospital outpatient evaluation and management (E&M) visits (-74%), new patient E&M visits (-70%), and established patient E&M visits (-60%). A decrease in billing frequency was observed for the top physician-administered oncology products, dropping in both April (-26%) and July (-31%). Mastectomies were reduced consistently in April through July, with colectomies similarly reduced in April and May and prostatectomies dipping in April and July.
Conclusion: The current impact of the COVID-19 pandemic on cancer care in the United States has resulted in decreases and delays in identifying new cancers and delivery of treatment. These problems, if unmitigated, will increase cancer morbidity and mortality for years to come.
Conflict of interest statementImpact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center .
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ( Open Payments ).
Debra Patt
Employment: Texas Oncology, McKesson, MedNax
Leadership: McKesson, Mednax, Texas Oncology
Stock and Other Ownership Interests: Mednax
Consulting or Advisory Role: Pfizer, Roche, AstraZeneca
Research Funding: Merck, Eisai, Seattle Genetics, Lilly
Travel, Accommodations, Expenses: McKesson
Lucio Gordan
Employment: Florida Cancer Specialists
Leadership: Florida Cancer Specialists
Honoraria: Ameris Pharma
Consulting or Advisory Role: Janssen Oncology
Speakers' Bureau: Myriad Genetics
Lance Grady
Employment: Avalere
Stock and Other Ownership Interests: INOVALON
Merrill Harmison
Employment: Avalere Health
Anan Zhou
Employment: Avalere Health, Analysis Group
No other potential conflicts of interest were reported.
FiguresFIG 1.
Relative change in billing frequencies…
FIG 1.
Relative change in billing frequencies for select cancer screening procedures (March-July 2019/2020). Billing…
FIG 1.Relative change in billing frequencies for select cancer screening procedures (March-July 2019/2020). Billing frequencies were determined by the following procedure codes: breast mammograms (77061, 77062, 77063, 77065, 77066, 77067); colon screening (45330, 81528, 82270, 82272, 82274, G0104, G0105, G0121, G0328); lung screening (31624, G0296, G0297); prostate screening (G0103).
FIG 2.
Relative change in billing frequencies…
FIG 2.
Relative change in billing frequencies for select physician-administered oncology products (at any site…
FIG 2.Relative change in billing frequencies for select physician-administered oncology products (at any site of services) and relative change in chemotherapy administration (by the site of service) (March-July 2019/2020). Billing frequency of the top 23 physician-administered oncology products (and respective biosimilars) as determined by 2018 Medicare Part B spend: Prolia/Xgeva, Neupogen (Zarxio, Nivestym), Somatuline Depot, Aloxi, Neulasta (Fulphila, Udenyca, Ziextenzo), Tecentriq, Bendeka, Avastin (Mvasi, Zirabev), Velcade, Adcetris, Kyprolis, Erbitux, Cyclophosphamide, Darzalex, Yervoy, Abraxane, Keytruda, Opdivo, Alimta, Perjeta, Rituxan (Truxima, Ruxience), Kadcyla, Herceptin (Ontruzant, Hersuma, Ogivri, Trazimera, Kanjinti).
FIG 3.
Relative change in billing frequencies…
FIG 3.
Relative change in billing frequencies for cancer-related biopsies and surgeries (March-July 2019/2020). Billing…
FIG 3.Relative change in billing frequencies for cancer-related biopsies and surgeries (March-July 2019/2020). Billing frequencies were classified by type of claim and identified by the following procedure codes: chemotherapy injection (96401, 96402, 96405, 96409); chemotherapy infusion (96413, 96415-96417); and chemotherapy administration (96420, 96425).
FIG 4.
Relative change in billing frequencies…
FIG 4.
Relative change in billing frequencies for cancer-related evaluation and management (E&M) services (March-July…
FIG 4.Relative change in billing frequencies for cancer-related evaluation and management (E&M) services (March-July 2019/2020). Billing frequencies were determined using a subset of highest-volume procedure codes for each of the following services: breast biopsy (19081-19085); colon biopsy (44389, 45380); lung biopsy (32405, 39402).
FIG 5.
Relative change in billing frequencies…
FIG 5.
Relative change in billing frequencies for cancer-related evaluation and management (E&M) services by…
FIG 5.Relative change in billing frequencies for cancer-related evaluation and management (E&M) services by setting of care (March-July 2019/2020). Billing frequencies were determined using a subset of highest-volume procedure codes for each of the following services: mastectomy (19301-19303, 19307); colectomy (44139, 44140, 44143, 44160, 44204, 44205, 44207, 44213); prostatectomy (52601, 52648, 55821, 55840, 55866).
FIG 6.
Total number of claims for…
FIG 6.
Total number of claims for cancer-related in-office evaluation and management (E&M) v telehealth…
FIG 6.Total number of claims for cancer-related in-office evaluation and management (E&M) v telehealth E&M services and relative change in billing frequencies (March-July 2019/2020). Billing frequencies were determined by the following procedure codes: new patient E&M (99201-99205); established patient E&M (99211-99215); hospital outpatient (G0463).
Similar articlesRanganathan P, Sengar M, Chinnaswamy G, Agrawal G, Arumugham R, Bhatt R, Bilimagga R, Chakrabarti J, Chandrasekharan A, Chaturvedi HK, Choudhrie R, Dandekar M, Das A, Goel V, Harris C, Hegde SK, Hulikal N, Joseph D, Kantharia R, Khan A, Kharde R, Khattry N, Lone MM, Mahantshetty U, Malhotra H, Menon H, Mishra D, Nair RA, Pandya SJ, Patni N, Pautu J, Pavamani S, Pradhan S, Thammineedi SR, Selvaluxmy G, Sharan K, Sharma BK, Sharma J, Singh S, Srungavarapu GC, Subramaniam R, Toprani R, Raman RV, Badwe RA, Pramesh CS; National Cancer Grid of India. Ranganathan P, et al. Lancet Oncol. 2021 Jul;22(7):970-976. doi: 10.1016/S1470-2045(21)00240-0. Epub 2021 May 27. Lancet Oncol. 2021. PMID: 34051879 Free PMC article.
Chen RC, Haynes K, Du S, Barron J, Katz AJ. Chen RC, et al. JAMA Oncol. 2021 Jun 1;7(6):878-884. doi: 10.1001/jamaoncol.2021.0884. JAMA Oncol. 2021. PMID: 33914015 Free PMC article.
Patt D, Gordan L, Patel K, Okon T, Ferreyros N, Markward N, Sullivan M, Burnett B, Getachew B, Harris C. Patt D, et al. Am J Manag Care. 2022 Apr;28(3 Spec. No.):SP136-SP138. doi: 10.37765/ajmc.2022.88855. Epub 2022 Mar 14. Am J Manag Care. 2022. PMID: 35285592
Kidwai N. Kidwai N. J Natl Med Assoc. 2022 Feb;114(1):12-15. doi: 10.1016/j.jnma.2021.08.033. Epub 2021 Sep 8. J Natl Med Assoc. 2022. PMID: 34507828 Free PMC article. Review. No abstract available.
Round T, Sethuraman L, Ashworth M, Purushotham A. Round T, et al. Br J Cancer. 2024 May;130(8):1233-1238. doi: 10.1038/s41416-024-02596-9. Epub 2024 Mar 15. Br J Cancer. 2024. PMID: 38491174 Free PMC article. Review.
Chen S, James SA, Hall S, Dang JH, Campbell JE, Chen MS Jr, Doescher MP. Chen S, et al. Front Public Health. 2023 Nov 3;11:1265071. doi: 10.3389/fpubh.2023.1265071. eCollection 2023. Front Public Health. 2023. PMID: 38026426 Free PMC article.
Shah W, O'Carroll O, Keane MP, McCarthy C. Shah W, et al. Respirology. 2021 May;26(5):509-510. doi: 10.1111/resp.14034. Epub 2021 Mar 7. Respirology. 2021. PMID: 33682239 Free PMC article.
Kato T, Katsuya R, Okado S, Sato K, Noritake O, Nakanishi K, Noguchi M, Kadomatsu Y, Ueno H, Ozeki N, Nakamura S, Fukumoto K, Chen-Yoshikawa TF. Kato T, et al. J Thorac Dis. 2023 Feb 28;15(2):542-551. doi: 10.21037/jtd-22-1289. Epub 2023 Feb 3. J Thorac Dis. 2023. PMID: 36910056 Free PMC article.
Kaur A, Pergolotti M, Battisti N, Krok-Schoen JL, Cabrera Chien L, Canin B, Malone MV, MacKenzie A, Ali I, Streck B, Shahrokni A, Plotkin E, Boehmer LB, BrintzenhofeSzoc K. Kaur A, et al. J Geriatr Oncol. 2023 Mar;14(2):101438. doi: 10.1016/j.jgo.2023.101438. Epub 2023 Jan 17. J Geriatr Oncol. 2023. PMID: 36682216 Free PMC article.
Van Dusen RA, Abernethy K, Chaudhary N, Paudyal V, Kurmi O. Van Dusen RA, et al. BMJ Open. 2023 Mar 17;13(3):e062734. doi: 10.1136/bmjopen-2022-062734. BMJ Open. 2023. PMID: 36931673 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3